"Jan. 15, 2013 -- Women who have migraine with aura may have a higher risk of heart attacks, and they may face a higher risk of dangerous blood clots if they use certain hormonal contraceptives.
Those are the findings from two newly pu"...
Patients (N = 269) have received single injections of 8 to 12 mg sumatriptan without significant adverse effects. Volunteers (N = 47) have received single subcutaneous doses of up to 16 mg without serious adverse events.
No gross overdoses in clinical practice have been reported. The half-life of elimination of sumatriptan is about 2 hours [see CLINICAL PHARMACOLOGY], and therefore monitoring of patients after overdose with subcutaneous sumatriptan should continue while symptoms or signs persist, and for at least 10 hours. It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of sumatriptan.
Sumavel DosePro is not designed to administer sumatriptan injection intravenously. Do not administer intravenously since sumatriptan may cause coronary vasospasm.
Ischemic or Vasospastic Coronary Artery Disease
Do not use Sumavel DosePro in patients with ischemic heart disease (e.g. angina pectoris, history of myocardial infarction, or documented silent ischemia), or in patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina or other significant underlying cardiovascular disease. [see WARNINGS AND PRECAUTIONS]
Do not use Sumavel DosePro in patients with cerebrovascular syndromes including (but not limited to) strokes of any type as well as transient ischemic attacks. [see WARNINGS AND PRECAUTIONS]
Peripheral Vascular Disease
Do not use Sumavel DosePro in patients with peripheral vascular disease including (but is not limited to) ischemic bowel disease. [see WARNINGS AND PRECAUTIONS]
Do not use within 24 hours of treatment with Ergotamine-Containing or Ergot-Type Medications or Other 5-HT1 Agonists (e.g. triptans)
Do not use Sumavel DosePro and any ergotamine-containing or ergot-type medication (such as dihydroergotamine or methysergide) within 24 hours of each other; do not use Sumavel DosePro and another 5-HT1 agonist (e.g. triptan) within 24 hours of each other (with the exception of a single dose of another sumatriptan product, provided the doses are separated by at least 1 hour) [see DRUG INTERACTIONS].
Hemiplegic or Basilar Migraine
Do not use Sumavel DosePro in patients with hemiplegic or basilar migraine.
Sumavel DosePro is contraindicated in patients with known hypersensitivity to sumatriptan.
Last reviewed on RxList: 8/2/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Sumavel DosePro Information
Sumavel DosePro - User Reviews
Sumavel DosePro User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find the secrets to longer life.